Gesellschaftsrecht / M&A

Kapitalmarkt

Wettbewerb

Steuern

Healthcare / Life Sciences

Homburger News

Homburger advises PolyPeptide in connection with the all-cash public tender offer launched by Samsung Biologics to acquire all publicly held registered shares of PolyPeptide

On July 20, 2026, PolyPeptide Group AG (SIX: PPGN), a specialized global Contract Development &amp; Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients, and Samsung Biologics Co., Ltd. announced that they have entered into a transaction agreement under which Samsung Biologics agreed to make an all-cash public tender offer to acquire all publicly held registered shares of PolyPeptide for CHF 44.31 per share. The offer values PolyPeptide’s equity at approximately CHF 1.46 bn. Samsung Biologics published its pre-announcement of the offer today. PolyPeptide’s largest individual shareholder, owning a stake of approximately 55.65% (excluding treasury shares), has committed to tender all of its shares into the offer.
The offer is subject to the satisfaction of customary offer conditions, including a minimum acceptance rate of 66.67% on a fully diluted share count basis and the receipt of regulatory approvals in certain jurisdictions.
Homburger is acting as legal counsel to PolyPeptide Group AG in connection with the transaction. The Homburger team is led by Frank Gerhard and included Micha Fankhauser, Nicola Togni, Patrick Schmidt, Matthias Müller, Pepe Hünerwadel, Matteo Gasser and Filippo Moggi (all Corporate / M&amp;A, Capital Markets), Richard Stäuber, Allegra Arnold and Anna-Katharina Leitz (all Competition), as well as Stefan Oesterhelt (Tax).

Arbeitsrecht und Vergütung für Führungskräfte

Immobilien

IP / IT

Finanzierungen

Homburger advises Consolidated Precision Products on its acquisition of the aerospace and industrial gas turbine operations from Georg Fischer

On July 7, 2026, Georg Fischer AG announced the signing of an agreement to divest the Precicast-Group, held by GF Casting Solutions Industrial SA, to Consolidated Precision Products Corp. (CPP). CPP is a US-based manufacturer of highly engineered castings and components for the aerospace, defense and industrial gas turbine industries. The transaction is expected to close toward the end of 2026, subject to customary closing conditions.
The Homburger team advising CPP on this transaction includes Anna Peter, Francesco Bernasconi, Tobias Gloor, Luca Ellenberger and Matteo Gasser (all Corporate / M&amp;A), Jeremy Reichlin and Claudine Schär (both Employment and Executive Compensation), Stefan Oesterhelt and Philippe Weber (both Tax), Stefan Gäumann and Olivier Bühlmann (both Real Estate), Luca Dal Molin and Berem Brun (both IP / IT), Stefan Bindschedler (Financing) as well as Allegra Arnold (Competition).

Matteo
Gasser

Homburger advises PolyPeptide in connection with the all-cash public tender offer launched by Samsung Biologics to acquire all publicly held registered shares of PolyPeptide

Homburger advises Consolidated Precision Products on its acquisition of the aerospace and industrial gas turbine operations from Georg Fischer

Join the Team

Matteo Gasser

Karriere

Sprachen

Zulassung

Teams

MatteoGasser

Homburger advises PolyPeptide in connection with the all-cash public tender offer launched by Samsung Biologics to acquire all publicly held registered shares of PolyPeptide

Homburger advises Consolidated Precision Products on its acquisition of the aerospace and industrial gas turbine operations from Georg Fischer

Join the Team

Matteo Gasser

Karriere

Sprachen

Zulassung

Teams

Matteo
Gasser